Finance
Dualyx: restoring the body’s balance in autoimmune diseases
Belgian start-up Dualyx is developing a novel approach with the potential to treat a wide range of autoimmune disorders. The […] May 12, 2022 · V-Bio Ventures
Drug development trends: from common to orphan indications… and back again?
Over the past few decades, pharma has gradually shifted its target patient focus for newly launched drugs from large to […] April 20, 2022 · V-Bio VenturesV-Bio Ventures raises EUR 110 million for its second fund and expands team
Ghent, Belgium, 31 March 2022 – V-Bio Ventures announced the final closing of its second fund, V-Bio Fund 2, having […] March 31, 2022 · V-Bio VenturesmiDiagnostics welcomes Nicolas De Clercq as its new Chief Financial Officer
Leuven, Belgium, 30 March 2022 – miDiagnostics, a fast-growing POC diagnostics company backed by Belgian Family Offices, announces today that Nicolas De […] March 30, 2022 · Turnstone CommunicationsNew incubator biotope by VIB launches to support biotech startup teams on their journey to success
Ghent, Belgium, 24 March 2022 – Incubator program biotope by VIB launches today to support biotech startup teams looking to impact people’s lives through […] March 24, 2022 · Turnstone CommunicationsQbic announces first close of new fund at EUR 49 million to invest in spin-offs from world-class knowledge partners
St-Denijs-Westrem, Belgium, 17 March 2022 – Qbic, an inter-university venture capital fund focusing on the transformation of technological breakthroughs into […] March 17, 2022 · Turnstone Communications
Antimicrobial Resistance – the hidden killer we’re ignoring
Antimicrobial Resistance has become an enormous challenge for global health, yet remains largely ignored by companies. As this deadly race […] March 16, 2022 · V-Bio VenturesV-Bio Ventures’ Portfolio Company Precirix raises EUR 80 million in Series B to advance its pipeline of precision radiopharmaceuticals
Ghent, Belgium, 16 March 2022 – V-Bio Ventures today announced the completion of a EUR 80 million Series B round […] March 16, 2022 · V-Bio Venturesflanders.healthTech launches 14 unique innovation projects in healthcare
Ghent, Belgium, 10 March 2022 – Following the launch of the cluster flanders.healthTech in 2021, the first round of 14 […] March 10, 2022 · Turnstone CommunicationsV-Bio Ventures’ Portfolio Company Syndesi Therapeutics Acquired by AbbVie to Strengthen its Neuroscience Portfolio
Ghent, Belgium, 1 March 2022 – V-Bio Ventures today announced the completion of the acquisition of its portfolio company Syndesi […] March 1, 2022 · V-Bio Ventures
When should a biotech hire a CFO?
February 16, 2022 · V-Bio VenturesNewton Biocapital launches a new fund with initial capital commitments of EUR 50 million and target size of EUR 150 million
Brussels, Belgium, 15 February 2022 – Newton Biocapital (“Newton”), a life sciences investor, announces the launch of its new fund […] February 15, 2022 · Turnstone CommunicationsV-Bio Ventures raises additional capital to support young biotech companies
Ghent, Belgium, 27 January 2022 – V-Bio Ventures, a venture capital company that focuses specifically on the segment of young […] January 27, 2022 · V-Bio Ventures
Economic Success: infinite growth is only possible in a diverse ecosystem
In recent public discussions on economic progress, people have been asking: is infinite growth really the best way to measure […] January 26, 2022 · V-Bio VenturesElmediX raises nearly 12 million euros to develop innovative heat technology to fight cancer
Mechelen, Belgium, January 25, 2022 – Belgian company ElmediX is developing intensive and controlled heat treatments for the treatment of […] January 25, 2022 · Turnstone Communications
Belgium: The Health & Biotech Valley of Today and Tomorrow
As part of the ‘Health & Biotech Valley of Tomorrow’ initiative, the Belgian government recently signed a charter together with […] December 15, 2021 · BioVoxV-Bio Ventures participates in the EUR 12 million seed round of heart failure biotech Corteria Pharmaceuticals
Ghent, Belgium, 9 December 2021 – Corteria Pharmaceuticals, a French biotechnology company specialized in the development of interceptive therapies for heart […] December 9, 2021 · V-Bio VenturesNew start-up Trince raises EUR 4 million for innovative technology to produce personalized cancer therapies safer, cheaper, and faster
Ghent, Belgium, 6 December 2021 – Trince, a spin-off of Ghent University (UGent), is developing innovative and efficient technology to insert […] December 6, 2021 · Turnstone Communications
Rejuvenate Biomed: Expanding peoples’ health spans by boosting cell resilience
Aging will affect each and every one of us at some point; it is part of the covenant of life. […] November 24, 2021 · Turnstone Communications
International pharmaceutical consultant Amador Bioscience picks Belgium for its first European base
For its first European base, pharmaceutical consultant Amador Bioscience has chosen to set up shop in Limburg province, Belgium. The […] November 24, 2021 · BioVoxBelgium has all the ingredients to be a top country for data science in health – but we have to act now!
– Science for health will connect decisionmakers with researchers, clinicians, and company leaders on the topic of data science in healthcare – The event […] November 15, 2021 · Turnstone Communications
Belgium has all the ingredients to be number one for real-world data in healthcare
Belgium is home to one of the world’s strongest health clusters and has long been ranked as the best country […] October 20, 2021 · BioVox
New GMOs on the horizon: say ‘cheese’!
To meet the challenges of climate change and global food demand, more VCs are investing in AgTech companies. A lot […] October 20, 2021 · V-Bio VenturesRejuvenate Biomed raises a EUR 15.7 million Series B to accelerate clinical development of its sarcopenia treatment for healthy aging
Heusden-Zolder, Belgium, Schlieren, Zürich, Switzerland, and Luxembourg, Grand Duchy of Luxembourg, 12 October 2021 – Rejuvenate Biomed NV (‘Rejuvenate’), a […] October 12, 2021 · Turnstone CommunicationsEsoBiotec ready to transform cell therapy cancer treatments
– EsoBiotec, a recently founded biotech company, announces a EUR 6 million pre-series A round comprised of non-dilutive funding from […] September 30, 2021 · Turnstone Communications
Biogen’s controversial Alzheimer’s drug approved by the FDA – what now?
It has been three months since the much-discussed FDA approval of Biogen’s Aduhelm, a treatment for Alzheimer’s Disease. The drug […] September 22, 2021 · V-Bio VenturesNewton Biocapital invests in PRISM BioLab to support development of a unique peptide mimetic technology platform to discover new drugs for intractable diseases
Brussels, Belgium / Tokyo, Japan – 9 September 2021 – Newton Biocapital (“Newton”), a life sciences investment fund active in […] September 9, 2021 · Turnstone Communications
Why keeping up with data science matters for our health
Data without science is nothing; just 1s and 0s, floating around a cloud waiting for someone to make sense of […] August 18, 2021 · BioVoxSpectricity Raises €14 Million Series B Funding as it Accelerates Plans to Deliver Industry Leading Hyperspectral Sensing to Mobile and Consumer Devices
Funding Expands Growth for Tiny Chip-size Sensors for Unimaginable New Applications. Mechelen, Belgium, August 3rd, 2021 – Spectricity, a leading provider of hyperspectral […] August 3, 2021 · Turnstone CommunicationsArdena’s success leads to major €35 million investment for expansion in Belgium, Sweden and The Netherlands
Ghent, Belgium, 14 July 2021 – Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO), in partnership with GHO Capital, […] July 14, 2021 · Turnstone CommunicationsAzalea Vision closes € 8 million Series A to develop a smart contact lens for light sensitivity and ocular disorders
Azalea Vision develops autonomous smart solutions embedded inside a contact lens to improve the quality of life of people with […] July 8, 2021 · Turnstone CommunicationsNewton Biocapital invests in EditForce to support development of a unique DNA/RNA editing platform based on PPR protein technology
Brussels, Belgium / Tokyo, Japan – 1 July 2021 – Newton Biocapital (“Newton”), a life sciences investment fund active in […] July 1, 2021 · Turnstone CommunicationsNewton Biocapital invests in NeuVasQ: EUR 20 million Series A to develop unique blood-brain barrier therapy
– Newton together with public and private investment partners invests in NeuVasQ for the development of blood-brain barrier pharmaceuticals based […] June 22, 2021 · Turnstone CommunicationsMontis Biosciences Awarded VLAIO Grant to Expand its Pipeline of Novel Immune-Oncology Therapeutics
Leuven, Belgium, 14 June 2021 – Montis Biosciences, a Belgium-based biotech company focused on the development of novel immuno-oncology therapeutics targeting the […] June 14, 2021 · Turnstone CommunicationsDroia Ventures raises a new fund of EUR 220 million to target genetic diseases and expands leadership team with George Golumbeski
Brussels, Belgium, 11 May 2021 – Droia Ventures today announced the final closing of its third fund, having raised EUR […] May 11, 2021 · Turnstone CommunicationsPulsify Medical closes second round Series A funding of EUR 6.35 million for wearable ultrasound heart monitor patch
Pulsify Medical is developing wearable ultrasound patches to monitor vital human organs such as the heart. The company has announced […] May 4, 2021 · Turnstone Communications
Belgian pharma industry among the EU’s strongest despite pandemic setbacks
How did the Belgian chemical and pharmaceutical sector fare during the first year of the pandemic? A report from essenscia […] April 28, 2021 · BioVox
To fund or not to fund: the psychology of investment decisions
Much has been written about the psychology of decision making and how venture capitalists choose which companies they want to […] April 28, 2021 · V-Bio VenturesV-Bio Ventures invests in new start-up Protealis to uplift sustainable plant protein production
Ghent, Belgium, 8 April 2021 – Today V-Bio Ventures announces its investment in Ghent-based company Protealis, a new spin-off from […] April 8, 2021 · V-Bio Ventures
AgomAb’s journey of growth in regenerative medicine
Ghent-based AgomAb Therapeutics recently raised a Series B of $74 million, the largest round ever for a Belgian biotech in […] March 31, 2021 · V-Bio Ventures
Augustine Therapeutics developing new medicines for neuromuscular diseases
Augustine Therapeutics had a lot of announcements this month: the VIB spin-off just appointed Dr. Sylvain Celanire as CEO, strengthened […] March 31, 2021 · Turnstone Communications
Wallonia to invest in plant-based proteins as meat substitutes
The Walloon region is taking major steps towards becoming an important player in the business of plant-based proteins. In the […] March 31, 2021 · BioVoxAugustine Therapeutics awarded EUR 1.2 million VLAIO research grant to develop new medicines for neuromuscular diseases
Leuven, Belgium, 23 March 2021 – Augustine Therapeutics, a biotech spin-out company from VIB that focuses on the development of […] March 23, 2021 · Turnstone Communications
Lessons learned from COVID-19: how do we prepare for the next pandemic?
Although the crisis has not yet passed, COVID-19 has already taught us many valuable lessons. This past year has tested […] March 10, 2021 · Turnstone CommunicationsRejuvenate Biomed Secures EUR 3.2 Million Series A Round to Advance Development of Healthy Aging Products
Heusden-Zolder, Belgium, 2 March 2021 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing prescription drugs for age-related diseases, announces […] March 2, 2021 · Turnstone Communications
V-Bio Ventures: a fresh fund with a difference
V-Bio Ventures recently announced their second fund, with the first closing already totaling 78 million euros [final close at 110 […] February 24, 2021 · V-Bio VenturesNewton Biocapital invests in Flemish start-up DeuterOncology
Brussels, Belgium, 24 February 2021 – Newton Biocapital I (“Newton Biocapital”), a life sciences investment fund active in Europe and […] February 24, 2021 · Turnstone CommunicationsOnco-immunology Company Pan Cancer T Launched as Spin-off from Erasmus Medical Center
– Dutch biotech company developing first-in-class T-cell Receptor (TCR) T-cell therapies – Seed investment by Swanbridge Capital and Van Herk […] February 8, 2021 · Turnstone CommunicationsV-Bio Ventures launches its second fund at EUR 78 million
– First Closing of V-Bio Fund 2 is announced at EUR 78 million – V-Bio Fund 2 will ensure seamless […] February 4, 2021 · V-Bio Ventures
The rapid evolution of Chinese biotech
The world is smaller today than it has ever been. With the COVID-19 pandemic, we have seen the advantages of […] December 2, 2020 · Turnstone Communications
Belgian biotechs partnering with China: deals of 2020
In 2019, a delegation of Belgian biotechs participated in an economic mission to China led by H.R.H. Princess Astrid. Co-organized […] December 2, 2020 · Turnstone Communications
Long-term loyalty: A Belgian fund’s perspective on Chinese investors
Over the past few years, an increasing number of European biotechs have been signing deals with Chinese investors. The Chinese […] December 2, 2020 · Turnstone CommunicationseTheRNA and China Grand Pharma enter a strategic collaboration in the Greater China Region focussed on eTheRNA’s proprietary mRNA development products and manufacturing capabilities
Niel, Belgium, 1 December 2020 – eTheRNA immunotherapies NV (“eTheRNA”) announced it has entered into a strategic cooperation and product […] December 2, 2020 · Turnstone CommunicationsNewton Biocapital I invests in Perseus Proteomics Inc. in Japan to develop therapeutic antibodies for the treatment of blood cancers
Brussels, Belgium / Tokyo, Japan – 1 December 2020 – Newton Biocapital I (“Newton”), a life sciences investment fund active in Europe […] December 1, 2020 · Turnstone Communications
A bridge from East to West: linking Chinese and European biotech
There are two main reasons why a European company might want to establish official links with a Chinese investor: funding, […] December 1, 2020 · Turnstone CommunicationsV-Bio Ventures invests in new start-up Animab in a EUR 3.4 million Seed Financing to improve health and performance of livestock animals
Gent, Belgium, 27 October 2020 – Today V-Bio Ventures announces its investment in Animab, a new venture spin-off from VIB, in a EUR […] October 27, 2020 · V-Bio Ventures
Belgium: the number one biotech country in Europe!
For the third year in a row, Belgium has been ranked the number one country in Europe for biotech! Belgium […] September 30, 2020 · BioVox
Countering COVID-19 with llama antibodies
In July 2020, VIB spin-off ExeVir Bio raised €23 million to advance a llama-derived antibody against COVID-19. The company is […] August 31, 2020 · BioVox
Belgian stem cell company GST bought by German pharmaceutical giant
The German pharmaceutical giant Boehringer Ingelheim has acquired GST, a stem cell specialist based in Belgium. A part of the […] August 31, 2020 · Turnstone CommunicationsBiodol Therapeutics receives EUR 4.5 million to progress its novel pain medication in a Series A led by V-Bio Ventures
V-Bio Ventures, a leading Belgian life sciences VC, invests in Biodol Therapeutics, a French biotech specialized in next-generation chronic pain […] August 31, 2020 · V-Bio VenturesNewton Biocapital I invests in J-Pharma Co., Ltd. in Japan focusing on drug development targeting L-type Amino Acid Transporter 1 (LAT1) for cancer and autoimmune diseases
Brussels, Belgium / Tokyo, Japan – 27 August 2020 – Newton Biocapital I (“Newton”), an investment company in life sciences, […] August 27, 2020 · Turnstone CommunicationsV-Bio invests into ExeVir Bio to accelerate development of new treatment conferring broad protection against Covid-19
Ghent, Belgium, 28 July 2020 – Today V-Bio Ventures announces its investment in a EUR 23 million Series A financing into ExeVir Bio. […] July 28, 2020 · V-Bio VenturesAnacura, a Belgian biotech company, sells stem cell business to Boehringer Ingelheim
Ghent, Belgium, 27 July 2020 – GST, the stem cell specialist for horses and pets within the Anacura Group, has […] July 27, 2020 · Turnstone Communications
Building bigger for Belgium’s maturing biotech scene
Biotech is booming in Belgium. To support the evolving needs of this world-class ecosystem, the Mariën family initiated and are […] July 7, 2020 · Turnstone Communications
VIB: the driving force behind a booming biotech ecosystem
Since VIB was established, the world class research institute has been led by a duo of managing directors. As Johan […] July 7, 2020 · BioVox
Cell therapies: opportunities and challenges
This article was authored by Christina Takke from V-Bio Ventures. Recent activities in the cell therapy field have prompted many […] May 5, 2020 · V-Bio Ventures
Potential impact of the corona crisis on the life sciences industry
This article was authored by Christina Takke from V-Bio Ventures Over the past few months, every news headline has focused […] March 26, 2020 · V-Bio VenturesMontis Biosciences launched with €8.4 million seed financing and a novel approach to immuno-oncology
Montis Biosciences announces its launch with €8,4 million in seed financing from an international investor syndicate to investigate interactions between perivascular macrophages [...] February 20, 2020 · Turnstone Communications
Predictions for Belgian Biotech in 2020
With the Belgian biotech landscape blooming, BioVox reached out to some of the investors in our network to see what their predictions are for the coming year. From trends to companies to keep an eye on, here’s their take on 2020! January 22, 2020 · BioVoxV-Bio Ventures invests in RootWave in a EUR 6.5 M Series A financing to develop and market electrical weed killing solutions
Today V-Bio Ventures announces its investment in RootWave, a pioneer in electrical weed killing solutions. RootWave secured ca. EUR 6.5m in a Series A investment round [...] January 20, 2020 · V-Bio Ventures
How business models shaped our current drug development trends
December 17, 2019 · V-Bio VenturesV-Bio Ventures invests in Augustine Therapeutics, a VIB and KU Leuven spin-off to fight neuromuscular diseases
Ghent, Belgium, December 16 2019 – Today V-Bio Ventures announces its investment in Augustine Therapeutics, a new venture developing innovative […] December 16, 2019 · V-Bio Ventures
Magic mushrooms in modern medicine
This article was authored by Katja Rosenkranz from V-Bio Ventures. More than 75 years after the initial discovery of lysergic acid […] November 26, 2019 · V-Bio Ventures
Pulsify Medical to develop a wearable heart monitor patch
Pulsify Medical, a joint imec and KU Leuven spin-off, has closed a seed funding round of €2.6 million. The investment, […] October 24, 2019 · Turnstone Communications
Closing the gender gap in biotech funding: a follow-up study
This article was authored by Christina Takke from V-Bio Ventures. In this follow-up to a previous VC Views article, V-Bio […] September 24, 2019 · V-Bio VenturesGalapagos-Gilead billion-dollar deal: beyond the numbers
Last month, Galapagos sealed a 5-billion-dollar deal with Gilead. Now that the dust has started to settle, we’re taking a […] August 27, 2019 · BioVox
The million-dollar question: How much do you charge for a lifesaving drug?
The newest generation of ground-breaking gene therapy drugs, Zolgensma and Zynteglo, come with eye-catching price tags [...] August 26, 2019 · V-Bio Ventures
How do we reduce the high cost of clinical trials?
Drug development is an exorbitantly expensive endeavor. A large expense factor for developing a new therapy is the high cost of conducting clinical trials. [...] July 18, 2019 · V-Bio Ventures
Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds
Ghent, Belgium, and Dresden, Germany – 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH […] July 3, 2019 · Turnstone Communications
Betting big on blood screens for early cancer detection
This article was authored by Ward Capoen from V-Bio Ventures. The American Society of Clinical Oncology (ASCO) just held their […] June 27, 2019 · V-Bio Ventures
OCTIMET Oncology tackling cancer with a new captain at the helm
In this article, V-Bio Ventures introduces one of their portfolio companies, OCTIMET. This Belgian oncology startup just added a new […] May 29, 2019 · V-Bio Ventures
Cultured meat, plant-based patties and bug burgers: VCs are backing protein alternatives
When it comes to food, our key sources of nutrition haven’t changed much in the last ten thousand years. Though hyped-up food trends and diets come and go, [...] April 16, 2019 · V-Bio Ventures
Closing the gender gap in biotech funding
Companies with a good gender balance consistently outperform those with only men in their management teams. [...] March 19, 2019 · V-Bio Ventures
Are we spending too much money on cancer drugs?
This article was authored by Ward Capoen from V-Bio Ventures. November is classically the month where immunotherapy takes center stage, […] January 22, 2019 · V-Bio Ventures
argenx signs billion-dollar deal with Janssen
Another Belgian biotech on the up and up: argenx just closed a billion-dollar deal with Janssen Pharmaceutica for their antibody […] December 4, 2018 · Turnstone Communications
Why start-ups can become mega companies in the pharma sector
In a previous BioVox article, we analyzed the steps needed for a life sciences start-up to turn into a fully […] November 20, 2018 · V-Bio Ventures
Are tech investments under threat by anti-science sentiments?
In biotech, company creation is usually preceded by scientific discoveries presenting solutions to existing problems. Because of this, early stage […] October 30, 2018 · V-Bio Ventures
Lessons in Herding Cats: Business Development for Life Sciences Companies
Business development challenges can make or break a company in any industry. For a life sciences company, overcoming the added […] October 16, 2018 · Janssen Pharmaceutica
Bringing clinical trials into the home
Lowering the costs of drug development is more important than ever; with the increasing pressure on drug pricing and billions […] October 2, 2018 · V-Bio Ventures
Galapagos and MorphoSys to receive up to EUR 850mil in deal with Novartis
Galapagos (Belgium) and MorphoSys (Germany) recently announced that they have entered into an exclusive global license agreement with Novartis. The […] July 31, 2018 · BioVox
Biotechs and subsidies - a fraught relationship
The ambition of any CEO heading a biotech start-up is to develop a new product and to reach patients quickly. […] July 23, 2018 · V-Bio Ventures
CD3 as co-creator of drugs with academia and pharma
The Center for Drug Design and Discovery (CD3), based in Leuven, bridges the gap between innovative biomedical research emerging from […] May 28, 2018 · Turnstone Communications
Acquisitions of Biotech companies: a good or a bad thing?
When on the 8th January 2018 the news travelled that Novo Nordisk made a €2.6bn bid for Belgium’s Ablynx, only […] May 14, 2018 · V-Bio Ventures
How to build a “European Amgen”
There are still very few large European biotech companies to compete with the Amgens and Gileads of the world. Only […] April 19, 2018 · V-Bio Ventures
Is innovation killing the pharmaceutical industry?
In the past few years, the speed at which new drugs have been coming to the market has accelerated significantly […] March 18, 2018 · V-Bio Ventures
After Ablynx, is an acquisition of Galapagos next?
The Gent biotech company Ablynx has been acquired by pharmaceutical giant Sanofi for 3.9 billion euros. The French Sanofi beat […] February 19, 2018 · BioVox
Rewind Therapeutics secures funding for Multiple Sclerosis research
Rewind Therapeutics, a privately held Belgian biotech company, completed a € 15.2 million Series A financing to develop novel re-myelinating […] January 11, 2018 · Turnstone Communications
New cures for hereditary diseases around the corner?
Hereditary diseases are caused by mutations or deletions in (single) genes that lead to either dysfunctional or inadequate levels of […] December 18, 2017 · V-Bio Ventures